Merrimack Pharmaceuticals, Inc (MACK)

$14.7

Market is closed - opens 8 PM, 28 Feb 2024

Insights on Merrimack Pharmaceuticals, Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 72.3% return, outperforming this stock by 44.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 246.6% return, outperforming this stock by 119.7%

Performance

  • $14.68
    $14.79
    $14.70
    downward going graph

    0.14%

    Downside

    Day's Volatility :0.74%

    Upside

    0.61%

    downward going graph
  • $11.25
    $15.89
    $14.70
    downward going graph

    23.47%

    Downside

    52 Weeks Volatility :29.2%

    Upside

    7.49%

    downward going graph

Returns

PeriodMerrimack Pharmaceuticals, IncSector (Health Care)Index (Russel 2000)
3 Months
13.95%
12.9%
0.0%
6 Months
19.12%
10.3%
0.0%
1 Year
27.6%
14.8%
-6.7%
3 Years
104.74%
30.6%
-19.6%

Highlights

Market Capitalization
210.9M
Book Value
$1.31
Earnings Per Share (EPS)
-0.1
PEG Ratio
0.07
Wall Street Target Price
4.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-8.7%
Return On Equity TTM
-8.96%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-9.1M
EBITDA
-2.8M
Diluted Eps TTM
-0.1
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 8 Wall street analysts offering stock ratings for Merrimack Pharmaceuticals, Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
4
4
4
Sell
4
4
4

Analyst Forecast

What analysts predicted

Downside of 72.79%

Current $14.70
Target $4.00

Technicals Summary

Sell

Neutral

Buy

Merrimack Pharmaceuticals, Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Merrimack Pharmaceuticals, Inc
Merrimack Pharmaceuticals, Inc
9.62%
19.12%
27.6%
104.74%
170.56%
Moderna, Inc.
Moderna, Inc.
-10.32%
-17.4%
-32.0%
-40.27%
325.43%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.5%
19.06%
30.55%
113.64%
128.3%
Novo Nordisk A/s
Novo Nordisk A/s
13.27%
31.73%
72.28%
239.12%
403.32%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.54%
23.29%
50.83%
106.05%
128.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Merrimack Pharmaceuticals, Inc
Merrimack Pharmaceuticals, Inc
NA
NA
0.07
0.0
-0.09
-0.09
NA
1.31
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.46
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.21
28.21
2.0
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.62
45.62
4.45
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.97
30.97
0.58
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Merrimack Pharmaceuticals, Inc
Merrimack Pharmaceuticals, Inc
Sell
$210.9M
170.56%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.9B
325.43%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$107.8B
128.3%
28.21
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.4B
403.32%
45.62
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$111.1B
128.38%
30.97
36.68%

Institutional Holdings

  • Western Standard LLC

    13.23%
  • Newtyn Management LLC

    13.08%
  • BlackRock Inc

    4.82%
  • Vanguard Group Inc

    4.19%
  • Madison Avenue Partners, LP

    3.86%
  • Dimensional Fund Advisors, Inc.

    3.04%

Corporate Announcements

  • Merrimack Pharmaceuticals, Inc Dividends June,2019

    In the quarter ending June,2019. Merrimack Pharmaceuticals, Inc has declared dividend of $0.5

    Read More
  • Merrimack Pharmaceuticals, Inc Earnings

    Merrimack Pharmaceuticals, Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.

Organization
Merrimack Pharmaceuticals, Inc
Employees
0
CEO
Mr. Gary L. Crocker M.B.A.
Industry
Health Technology

FAQs